
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8335301/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Incidence of Malignancies Among Patients With Chronic Hepatitis B in US Health Care Organizations, 2006–2018. Journal of Infectious Diseases, 2022, 226, 896-900.	4.0	7
2	Lower Rates of Emergency Department Visits and Hospitalizations Among Patients With Chronic Hepatitis C With Sustained Virological Response to Interferon-Free Direct-Acting Antiviral Therapy (2014–2018). Clinical Infectious Diseases, 2022, 75, 1453-1456.	5.8	1
3	Psychosocial Obstacles to Hepatitis C Treatment Initiation Among Patients in Care: A Hitch in the Cascade of Cure. Hepatology Communications, 2021, 5, 400-411.	4.3	14
4	The Persistence of Underreporting of Hepatitis C as an Underlying or Contributing Cause of Death, 2011–2017. Clinical Infectious Diseases, 2021, 73, 891-894.	5.8	2
5	Trends in Cirrhosis and Mortality by Age, Sex, Race, and Antiviral Treatment Status Among US Chronic Hepatitis B Patients (2006-2016). Journal of Clinical Gastroenterology, 2021, Publish Ahead of Print, .	2.2	4
6	Health Insurance Status of Adults with Hepatitis in the United States: Implications of Results from the National Health Interview Survey, 2013–2018. Population Health Management, 2021, 24, 651-653.	1.7	0
7	Unexpected Hepatitis B Virus Infection After Liver Transplantation — United States, 2014–2019. Morbidity and Mortality Weekly Report, 2021, 70, 961-966.	15.1	4
8	Unexpected hepatitis B virus infection after liver transplantation — United States, 2014–2019. American Journal of Transplantation, 2021, 21, 3190-3195.	4.7	0
9	Low Uptake of Direct-acting Antiviral Therapy Among Hepatitis C Patients With Advanced Liver Disease and Access to Care, 2014-2017. Journal of Clinical Gastroenterology, 2021, 55, 77-83.	2.2	11
10	Mental and physical health status among chronic hepatitis B patients. Quality of Life Research, 2020, 29, 1567-1577.	3.1	16
11	Assessing Solid Organ Donors and Monitoring Transplant Recipients for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection — U.S. Public Health Service Guideline, 2020. MMWR Recommendations and Reports, 2020, 69, 1-16.	61.1	63
12	Testing and Clinical Management of Health Care Personnel Potentially Exposed to Hepatitis C Virus — CDC Guidance, United States, 2020. MMWR Recommendations and Reports, 2020, 69, 1-8.	61.1	21
13	Hepatitis B Virus Mutant Infections in Hemodialysis Patients: A Case Series. Kidney Medicine, 2019, 1, 347-353.	2.0	2
14	Underreporting of Hepatitis B and C virus infections — Pennsylvania, 2001–2015. PLoS ONE, 2019, 14, e0217455.	2.5	4
15	Trends in Diagnosed Chronic Hepatitis B in a US Health System Population, 2006–2015. Open Forum Infectious Diseases, 2019, 6, ofz286.	0.9	5
16	Hepatitis B and C virus infections transmitted through organ transplantation investigated by CDC, United States, 2014-2017. American Journal of Transplantation, 2019, 19, 2570-2582.	4.7	23
17	Quantifying the risk of undetected HIV, hepatitis B virus, or hepatitis C virus infection in Public Health Service increased risk donors. American Journal of Transplantation, 2019, 19, 2583-2593.	4.7	21
18	Characteristics of Deceased Solid Organ Donors and Screening Results for Hepatitis B, C, and Human Immunodeficiency Viruses — United States, 2010–2017. Morbidity and Mortality Weekly Report, 2019, 68, 61-66.	15.1	43

#	Article	IF	CITATIONS
19	Mortality Among Patients With Chronic Hepatitis B Infection: The Chronic Hepatitis Cohort Study (CHeCS). Clinical Infectious Diseases, 2019, 68, 956-963.	5.8	37
20	Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes. Alimentary Pharmacology and Therapeutics, 2019, 49, 599-608.	3.7	39
21	Sustained virological response does not improve longâ€ŧerm glycaemic control in patients with type 2 diabetes and chronic hepatitis C. Liver International, 2019, 39, 1027-1032.	3.9	17
22	The Hepatitis C Virus Care Continuum: Linkage to Hepatitis C Virus Care and Treatment Among Patients at an Urban Health Network, Philadelphia, PA. Hepatology, 2019, 70, 476-486.	7.3	55
23	Race, Age, and Geography Impact Hepatitis C Genotype Distribution in the United States. Journal of Clinical Gastroenterology, 2019, 53, 40-50.	2.2	16
24	Hepatitis B Virus Infection and Hepatitis C Virus Treatment inÂa Large Cohort of HepatitisÂC–Infected Patients in the United States. Gastroenterology, 2018, 154, 754-758.	1.3	5
25	Changing trends in complications of chronic hepatitis C. Liver International, 2018, 38, 239-247.	3.9	12
26	Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015. Journal of Clinical Gastroenterology, 2018, 52, 641-647.	2.2	39
27	The Predictive Value of International Classification of Disease Codes for Chronic Hepatitis C Virus Infection Surveillance: The Utility and Limitations of Electronic Health Records. Population Health Management, 2018, 21, 110-115.	1.7	8
28	Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection. Infectious Disease Clinics of North America, 2018, 32, 253-268.	5.1	20
29	Need for Increasing Hepatitis A Virus Vaccination Among Patients Infected With Hepatitis B Virus and Hepatitis CÂVirus. Gastroenterology, 2018, 154, 2015-2017.	1.3	8
30	Detection, Reporting, and Treatment of Hepatitis C Infections Among Hemodialysis Patients. Infection Control and Hospital Epidemiology, 2017, 38, 493-494.	1.8	2
31	Prevalence of false-positive hepatitis C antibody results, National Health and Nutrition Examination Study (NHANES) 2007–2012. Journal of Clinical Virology, 2017, 89, 1-4.	3.1	50
32	A Point System to Forecast Hepatocellular Carcinoma Risk Before and After Treatment Among Persons with Chronic Hepatitis C. Digestive Diseases and Sciences, 2017, 62, 3221-3234.	2.3	2
33	Comparison of ICD-9 Codes for Depression and Alcohol Misuse to Survey Instruments Suggests These Codes Should Be Used with Caution. Digestive Diseases and Sciences, 2017, 62, 2704-2712.	2.3	18
34	Longâ€ŧerm progression of viral load and serum markers of fibrosis among treated and untreated patients with chronic hepatitis B. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1250-1257.	2.8	9
35	Transmission of Hepatitis A Virus through Combined Liver–Small Intestine–Pancreas Transplantation. Emerging Infectious Diseases, 2017, 23, 590-596.	4.3	17
36	<i>Notes from the Field:</i> Hepatitis C Transmission from Inappropriate Reuse of Saline Flush Syringes for Multiple Patients in an Acute Care General Hospital — Texas, 2015. Morbidity and Mortality Weekly Report, 2017, 66, 258-260.	15.1	14

#	Article	IF	CITATIONS
37	Higher allâ€cause hospitalization among patients with chronic hepatitis C: the Chronic Hepatitis Cohort Study (<scp>CH</scp> e <scp>CS</scp>), 2006–2013. Journal of Viral Hepatitis, 2016, 23, 748-754.	2.0	13
38	Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma. Journal of Viral Hepatitis, 2016, 23, 718-729.	2.0	30
39	Prevalence of Renal Impairment and Associated Conditions Among HCV-Infected Persons in the Chronic Hepatitis Cohort Study (CHeCS). Digestive Diseases and Sciences, 2016, 61, 2087-2093.	2.3	17
40	Hepatitis B Reverse Seroconversion and Transmission inÂaÂHemodialysis Center: A Public Health Investigation andÂCaseÂReport. American Journal of Kidney Diseases, 2016, 68, 292-295.	1.9	14
41	Distribution of disease phase, treatment prescription and severe liver disease among 1598 patients with chronic hepatitis B in the Chronic Hepatitis Cohort Study, 2006–2013. Alimentary Pharmacology and Therapeutics, 2016, 44, 1080-1089.	3.7	21
42	Infrequent Clinical Assessment of Chronic Hepatitis B Patients in United States General Healthcare Settings: Table 1 Clinical Infectious Diseases, 2016, 63, ciw516.	5.8	33
43	Frequency of and Factors Associated with Receipt of Liver-Related Specialty Care Among Patients with Hepatitis C in the Chronic Hepatitis Cohort Study. Digestive Diseases and Sciences, 2016, 61, 3469-3477.	2.3	5
44	Prevalence of False-Positive Hepatitis C Antibody Tests in the National Health and Nutrition Examination Survey (NHANES), 2007–2012. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
45	Transmission of blood-borne pathogens in US dental health care settings. Journal of the American Dental Association, 2016, 147, 729-738.	1.5	113
46	Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response toÂTreatment for HCV Infection. Clinical Gastroenterology and Hepatology, 2016, 14, 1044-1055.e3.	4.4	49
47	All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus. Clinical Infectious Diseases, 2016, 62, 289-297.	5.8	61
48	<i>Notes from the Field</i> : Health Care–Associated Hepatitis A Outbreak — Texas, 2015. Morbidity and Mortality Weekly Report, 2016, 65, 425-426.	15.1	5
49	Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: The Chronic Hepatitis Cohort Study (CHeCS). Hepatology, 2015, 61, 802-811.	7.3	62
50	Incident hepatitis among repeat blood donors: A sentinel event signaling possible health care–associated infection and need for reporting to public health authorities. Transfusion, 2015, 55, 2531-2533.	1.6	0
51	Prevalence of Cirrhosis in Hepatitis C Patients in the Chronic Hepatitis Cohort Study (CHeCS): A Retrospective and Prospective Observational Study. American Journal of Gastroenterology, 2015, 110, 1169-1177.	0.4	33
52	Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006–2010. Journal of Hepatology, 2015, 63, 822-828.	3.7	138
53	Late diagnosis of hepatitis C virus infection in the Chronic Hepatitis Cohort Study (CHeCS): Missed opportunities for intervention. Hepatology, 2015, 61, 1479-1484.	7.3	41
54	Continued Rising Mortality From Hepatitis C Virus in the United States, 2003–2013. Open Forum Infectious Diseases, 2015, 2, .	0.9	0

#	Article	IF	CITATIONS
55	Comparative Effectiveness Research of Chronic Hepatitis B and C Cohort Study (CHeCS): Improving Data Collection and Cohort Identification. Digestive Diseases and Sciences, 2014, 59, 3053-3061.	2.3	9
56	Reported reasons for testing among hepatitis B virusâ€infected patients – Chronic Hepatitis Cohort Study (<scp>CH</scp> e <scp>CS</scp>), United States, 2006–2010. Liver International, 2014, 34, e162-3.	3.9	5
57	Trends in HCV RNA Testing Among HCV Antibody-Positive Persons in Care, 2003-2010. Clinical Infectious Diseases, 2014, 59, 976-981.	5.8	25
58	Mortality Among Persons in Care With Hepatitis C Virus Infection: The Chronic Hepatitis Cohort Study (CHeCS), 2006-2010. Clinical Infectious Diseases, 2014, 58, 1055-1061.	5.8	108
59	<scp>APRI</scp> and <scp>FIB</scp> â€4 are good predictors of the stage of liver fibrosis in chronic hepatitis <scp>B</scp> : the Chronic Hepatitis Cohort Study (<scp>CH</scp> e <scp>CS</scp>). Journal of Viral Hepatitis, 2014, 21, 917-920.	2.0	88
60	Hepatitis B vaccine immunogenicity among adults vaccinated during an outbreak response in an assisted living facility—Virginia, 2010. Vaccine, 2014, 32, 852-856.	3.8	8
61	Antiviral Therapy for Chronic Hepatitis B Virus Infection and Development of Hepatocellular Carcinoma in a US Population. Clinical Gastroenterology and Hepatology, 2014, 12, 885-893.	4.4	124
62	Hepatitis B virus infection testing and prevalence among Asian and Pacific Islanders. American Journal of Managed Care, 2014, 20, e98-e104.	1.1	16
63	Hepatitis C in the United States. New England Journal of Medicine, 2013, 368, 1859-1861.	27.0	279
64	Acute Hepatitis B Outbreaks in 2 Skilled Nursing Facilities and Possible Sources of Transmission: North Carolina, 2009–2010. Infection Control and Hospital Epidemiology, 2013, 34, 709-716.	1.8	5
65	Use of the International Classification of Diseases, 9th revision, coding in identifying chronic hepatitis B virus infection in health system data: implications for national surveillance. Journal of the American Medical Informatics Association: JAMIA, 2013, 20, 441-445.	4.4	17
66	Noninvasive Serum Fibrosis Markers for Screening and Staging Chronic Hepatitis C Virus Patients in a Large US Cohort. Clinical Infectious Diseases, 2013, 57, 240-246.	5.8	118
67	Baseline Characteristics and Mortality Among People in Care for Chronic Viral Hepatitis: The Chronic Hepatitis Cohort Study. Clinical Infectious Diseases, 2013, 56, 40-50.	5.8	159
68	Hepatitis B virus transmissions associated with a portable dental clinic, West Virginia, 2009. Journal of the American Dental Association, 2013, 144, 1110-1118.	1.5	30
69	Hepatitis C virus. Journal of the American Dental Association, 2013, 144, 1340-1347.	1.5	16
70	Hepatitis B and C Virus Infection Among 1.2 Million Persons With Access to Care: Factors Associated With Testing and Infection Prevalence. Clinical Infectious Diseases, 2012, 55, 1047-1055.	5.8	154
71	Hepatitis B vaccination of susceptible elderly residents of long term care facilities during a hepatitis B outbreak. Vaccine, 2012, 30, 3147-3150.	3.8	35
72	Outbreak of Hepatitis B Virus Infections Associated with Assisted Monitoring of Blood Glucose in an Assisted Living Facility–Virginia, 2010. PLoS ONE, 2012, 7, e50012.	2.5	19

#	Article	IF	CITATIONS
73	Investigation of Hepatitis B Virus and Human Immunodeficiency Virus Transmission among Severely Mentally III Residents at a Long Term Care Facility. PLoS ONE, 2012, 7, e43252.	2.5	7
74	Trends in Hepatitis C Virus Infection Among Patients in the HIV Outpatient Study, 1996–2007. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 388-396.	2.1	47
75	Renal Function in Patients with Preexisting Renal Disease Receiving Tenofovir-Containing Highly Active Antiretroviral Therapy in the HIV Outpatient Study. AIDS Patient Care and STDs, 2009, 23, 589-592.	2.5	28
76	Nonhospital Health Care–Associated Hepatitis B and C Virus Transmission: United States, 1998–2008. Annals of Internal Medicine, 2009, 150, 33.	3.9	243
77	Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994–2005. Aids, 2008, 22, 1345-1354.	2.2	120
78	Initiation of Antiretroviral Therapy at CD4 Cell Counts ≥350 Cells/mm3 Does Not Increase Incidence or Risk of Peripheral Neuropathy, Anemia, or Renal Insufficiency. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 27-35.	2.1	71
79	Incidence of Types of Cancer among HIV-Infected Persons Compared with the General Population in the United States, 1992–2003. Annals of Internal Medicine, 2008, 148, 728.	3.9	824
80	US Cohorts review: The HIV Outpatient Study (HOPS) and the Multicenter AIDS Cohort Study (MACS). , 2008, , 171-184.		0
81	Renal Function in Tenofovir-Exposed and Tenofovir-Unexposed Patients Receiving Highly Active Antiretroviral Therapy in the HIV Outpatient Study. Journal of the International Association of Providers of AIDS Care, 2007, 6, 178-187.	1.2	43
82	HIV Genotypic Resistance Testing to Optimize Antiretroviral Prescribing: Is There Room for Improvement?. Antiviral Therapy, 2007, 12, 957-962.	1.0	3
83	Short-Term Safety and Tolerability of Didanosine Combined with High- versus Low-Dose Tenofovir Disproxil Fumarate in Ambulatory HIV-1–Infected Persons. AIDS Patient Care and STDs, 2006, 20, 238-244.	2.5	11
84	Mortality in the Highly Active Antiretroviral Therapy Era. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 27-34.	2.1	1,268
85	The changing spectrum of pulmonary disease in patients with HIV infection on antiretroviral therapy. Aids, 2006, 20, 1095-1107.	2.2	89
86	Increased Body Mass Index Does Not Alter Response to Initial Highly Active Antiretroviral Therapy in HIV-1-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 35-41.	2.1	30
87	Renal Function in Patients Receiving Tenofovir With Ritonavir/Lopinavir or Ritonavir/Atazanavir in the HIV Outpatient Study (HOPS) Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 626-628.	2.1	38
88	Modification of the Incidence of Drug-Associated Symmetrical Peripheral Neuropathy by Host and Disease Factors in the HIV Outpatient Study Cohort. Clinical Infectious Diseases, 2005, 40, 148-157.	5.8	142
89	Factors Related to and Consequences of Adherence to Antiretroviral Therapy in an Ambulatory HIV-Infected Patient Cohort. AIDS Patient Care and STDs, 2004, 18, 721-727.	2.5	19
90	Hepatitis A and B Vaccination Practices for Ambulatory Patients Infected with HIV. Clinical Infectious Diseases, 2004, 38, 1478-1484.	5.8	122

#	Article	IF	CITATIONS
91	Factors associated with chronic renal failure in HIV-infected ambulatory patients. Aids, 2004, 18, 2171-2178.	2.2	54
92	A 7-year longitudinal analysis of IL-2 in patients treated with highly active antiretroviral therapy. Aids, 2004, 18, 2346-2348.	2.2	3
93	Influence of Coinfection with Hepatitis C Virus on Morbidity and Mortality Due to Human Immunodeficiency Virus Infection in the Era of Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2003, 36, 363-367.	5.8	168
94	Factors Associated with Maintenance of Long-Term Plasma Human Immunodeficiency Virus RNA Suppression. Clinical Infectious Diseases, 2003, 37, 702-707.	5.8	18
95	Incidence of and Risk Factors for Lipoatrophy (Abnormal Fat Loss) in Ambulatory HIV-1-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 32, 48-56.	2.1	207
96	Does Prior Short-Course Nevirapine Reduce the Effectiveness of Subsequent Combination Treatment With Efavirenz?. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 348-350.	2.1	2
97	Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata. Annals of Internal Medicine, 2003, 138, 620.	3.9	372
98	Prevalence and clinical correlates of HIV viremia (blips') in patients with previous suppression below the limits of quantification. Aids, 2002, 16, 2035-2041.	2.2	88
99	Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. Aids, 2002, 16, 1617-1626.	2.2	129
100	Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet, The, 2002, 360, 1747-1748.	13.7	471
101	Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. Aids, 2001, 15, 1389-1398.	2.2	379
102	Possible bias of ascertainment in assessing chemoprophylaxis for cryptosporidiosis. Aids, 2001, 15, 1589.	2.2	2
103	Factors associated with the successful modification of antiretroviral therapy. Aids, 2000, 14, 491-497.	2.2	16
104	Discontinuation of Chemoprophylaxis against <i>Pneumocystis carinii</i> Pneumonia in Patients with HIV Infection. Annals of Internal Medicine, 2000, 132, 201.	3.9	41
105	Influence of human immunodeficiency virus infection on pelvic inflammatory disease. Obstetrics and Gynecology, 2000, 95, 525-534.	2.4	68
106	Changing Conditions and Treatments in a Dynamic Cohort of Ambulatory HIV Patients. Annals of Epidemiology, 1999, 9, 349-357.	1.9	70
107	Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection. New England Journal of Medicine, 1998, 338, 853-860.	27.0	8,991
108	Pneumocystis carinii Pneumonia Incidence and Chemoprophylaxis Failure in Ambulatory HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes, 1998, 19, 182-188.	0.3	27

#	Article	IF	CITATIONS
109	HIV Nursing and Symptom Management Emerging Infectious Diseases, 1998, 4, 710-710.	4.3	0